Oncolytics Biotech

Companies Oncolytics Biotech

News Oncolytics Biotech

• Oncolytics Biotech Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial

  Oncolytics Biotech Inc. announced that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and P more

• Oncolytics Biotech Inc. Announces Publication of Preclinical Research on Combination of Antiangiogenic Cancer Therapy

  Oncolytics Biotech Inc. announced that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin more

• Oncolytics Biotech Inc. Appoints Senior Vice President, Global Licensing and Business Development

  Oncolytics Biotech Inc. announced the appointment of Dr. Alan Warrander to the role of Senior Vice President, Global Licensing and Business Development. In his 32-year career, Dr. Warrander has held a number of positions within the biotechnology and pharmaceutical industries. He held a number of p more

Publications Oncolytics Biotech

• Clinical trials involving the oncolytic virus, reovirus: ready for prime time?

  Evaluation of: Karapanagiotou EM, Roulstone V, Twigger K et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin. Cancer Res. 18(7), 2080–2089 (2012). The use of oncolytic viruses as a potentia more

Market studies Oncolytics Biotech

• Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Osteosarcoma Therapeutics market. The report identifies more

Websites Oncolytics Biotech